Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

Key Inclusion Criteria:

- Established diagnosis of hypertrophic cardiomyopathy defined by standard criteria as a
maximal left ventricular wall thickness ≥ 15 mm at initial diagnosis

- Exertional symptoms including at least one of the following:

- New York Heart Association (NYHA) Class ≥ II dyspnea

- Canadian Cardiovascular Society (CCS) Class ≥ II angina

- Screening (baseline) peak VO2 < 80% of predicted for age, sex, and weight

- Ability to perform an upright treadmill cardiopulmonary exercise test (CPET)

Key Exclusion Criteria:

- Known aortic valve stenosis (moderate or severe)

- Known coronary artery disease

- Left ventricular systolic dysfunction (ejection fraction < 50%)

- Recent septal reduction procedure (ie, surgical myectomy or alcohol septal ablation)
within six months prior to screening or such a procedure scheduled to occur during the
study

Note: Other protocol defined Inclusion/Exclusion criteria may apply.